The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial
Background: Referral to weight loss programmes is the only effective treatment for non-alcoholic fatty liver disease (NAFLD). Clinicians should advise weight loss and screen for liver fibrosis using the Enhanced Liver Fibrosis (ELF) score. Aim: To examine if the ELF score changes with weight loss. D...
Main Authors: | Dimitrios A. Koutoukidis, Susan A. Jebb, Paul Aveyard, Nerys M. Astbury |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-03-01
|
Series: | Obesity Facts |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/505667 |
Similar Items
-
Heterogeneity in the uptake, attendance, and outcomes in a clinical trial of a total diet replacement weight loss programme
by: Nerys M. Astbury, et al.
Published: (2020-04-01) -
Biomarkers for liver fibrosis: Advances, advantages and disadvantages
by: A. Cequera, et al.
Published: (2014-07-01) -
From liver biopsy to non-invasive markers in evaluating fibrosis in chronic liver disease
by: Cătălina Diaconu, et al.
Published: (2015-08-01) -
Skin Biomarkers for Cystic Fibrosis: A Potential Non-Invasive Approach for Patient Screening
by: Cibele Zanardi Esteves, et al.
Published: (2018-01-01) -
Biomarkers in patients with myocardial fibrosis
by: An Zhe, et al.
Published: (2017-10-01)